CLINICAL TRIALS PROFILE FOR NATALIZUMAB
✉ Email this page to a colleague
All Clinical Trials for natalizumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00027300 ↗ | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Completed | Elan Pharmaceuticals | Phase 3 | 2001-11-01 | The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. |
| NCT00027300 ↗ | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Completed | Biogen | Phase 3 | 2001-11-01 | The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. |
| NCT00030966 ↗ | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Completed | Elan Pharmaceuticals | Phase 3 | 2002-01-01 | The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS). |
| NCT00030966 ↗ | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Completed | Biogen | Phase 3 | 2002-01-01 | The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS). |
| NCT00032786 ↗ | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Completed | Elan Pharmaceuticals | Phase 3 | 2002-03-01 | The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for natalizumab
Condition Name
Clinical Trial Locations for natalizumab
Trials by Country
Clinical Trial Progress for natalizumab
Clinical Trial Phase
Clinical Trial Sponsors for natalizumab
Sponsor Name
